Stock Scorecard



Stock Summary for Verve Therapeutics Inc (VERV) - $5.22 as of 3/28/2025 9:17:10 PM EST

Total Score

13 out of 30

Safety Score

38 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VERV

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VERV

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VERV

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for VERV

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for VERV (38 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 6
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for VERV

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose - Verve Therapeutics ( NASDAQ:VERV ) 3/24/2025 11:00:00 AM
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose 3/24/2025 11:00:00 AM
Verve Therapeutics ( VERV ) Reports Q4 Loss, Tops Revenue Estimates 2/27/2025 1:25:00 PM
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Verve Therapeutics ( NASDAQ:VERV ) 2/27/2025 12:00:00 PM
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Verve Therapeutics ( NASDAQ:VERV ) 1/29/2025 12:00:00 PM
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference 1/29/2025 12:00:00 PM
Verve Therapeutics ( VERV ) Moves 18.7% Higher: Will This Strength Last? 1/23/2025 2:31:00 PM
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones - Verve Therapeutics ( NASDAQ:VERV ) 1/13/2025 12:00:00 PM
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Verve Therapeutics ( NASDAQ:VERV ) 1/8/2025 12:00:00 PM
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 1/3/2025 9:05:00 PM

Financial Details for VERV

Company Overview

Ticker VERV
Company Name Verve Therapeutics Inc
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 5.22
Price 4 Years Ago 36.87
Last Day Price Updated 3/28/2025 9:17:10 PM EST
Last Day Volume 585,355
Average Daily Volume 1,268,353
52-Week High 13.24
52-Week Low 4.30
Last Price to 52 Week Low 21.40%

Valuation Measures

Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -4.47
Free Cash Flow Ratio 0.86
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 13.05
Total Cash Per Share 6.08
Book Value Per Share Most Recent Quarter 5.56
Price to Book Ratio 0.95
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 14.50
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 88,796,000
Market Capitalization 463,515,120
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -27.12%
Reported EPS 12 Trailing Months -2.35
Reported EPS Past Year -2.35
Reported EPS Prior Year -3.12
Net Income Twelve Trailing Months -197,026,000
Net Income Past Year -200,068,000
Net Income Prior Year -157,387,000
Quarterly Revenue Growth YOY 154.30%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -428.70%

Balance Sheet

Total Cash Most Recent Quarter 539,900,000
Total Cash Past Year 624,000,000
Total Cash Prior Year 554,800,000
Net Cash Position Most Recent Quarter 539,900,000
Net Cash Position Past Year 624,000,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 599,502,000
Total Stockholder Equity Prior Year 550,932,000
Total Stockholder Equity Most Recent Quarter 508,551,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -162,061,000
Free Cash Flow Per Share Twelve Trailing Months -1.83
Free Cash Flow Past Year -158,832,000
Free Cash Flow Prior Year -135,564,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.34
MACD Signal -0.29
20-Day Bollinger Lower Band 4.33
20-Day Bollinger Middle Band 6.38
20-Day Bollinger Upper Band 8.42
Beta 1.78
RSI 40.21
50-Day SMA 6.07
150-Day SMA 14.60
200-Day SMA 0.00

System

Modified 3/28/2025 10:23:58 AM EST